Cambridge Investment Research Advisors buys $48,689,781 stake in Diplomat Pharmacy Inc (DPLO)

Diplomat Pharmacy Inc (DPLO) : Cambridge Investment Research Advisors scooped up 1,175,784 additional shares in Diplomat Pharmacy Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 3, 2016. The investment management firm now holds a total of 1,700,656 shares of Diplomat Pharmacy Inc which is valued at $48,689,781.Diplomat Pharmacy Inc makes up approximately 1.10% of Cambridge Investment Research Advisors’s portfolio.

Other Hedge Funds, Including , Columbus Circle Investors sold out all of its stake in DPLO during the most recent quarter. The investment firm sold 438,070 shares of DPLO which is valued $12,541,944. Diversified Trust Co sold out all of its stake in DPLO during the most recent quarter. The investment firm sold 6,862 shares of DPLO which is valued $196,459.Ifp Advisors Inc reduced its stake in DPLO by selling 75 shares or 24.59% in the most recent quarter. The Hedge Fund company now holds 230 shares of DPLO which is valued at $6,585.Moody Lynn Lieberson reduced its stake in DPLO by selling 425 shares or 2.77% in the most recent quarter. The Hedge Fund company now holds 14,915 shares of DPLO which is valued at $427,016. Diplomat Pharmacy Inc makes up approx 0.07% of Moody Lynn Lieberson’s portfolio. Texas Permanent School Fund added DPLO to its portfolio by purchasing 25,246 company shares during the most recent quarter which is valued at $764,701. Diplomat Pharmacy Inc makes up approx 0.01% of Texas Permanent School Fund’s portfolio.

Diplomat Pharmacy Inc opened for trading at $31.16 and hit $31.58 on the upside on Tuesday, eventually ending the session at $31.42, with a gain of 7.09% or 2.08 points. The heightened volatility saw the trading volume jump to 15,16,947 shares. Company has a market cap of $2,073 M.

On the company’s financial health, Diplomat Pharmacy Inc reported $0.23 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on May 9, 2016. Analyst had a consensus of $0.18. The company had revenue of $995.90 million for the quarter, compared to analysts expectations of $982.32 million. The company’s revenue was up 59.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.09 EPS.

Many Wall Street Analysts have commented on Diplomat Pharmacy Inc. Company shares were Reiterated by Mizuho on May 11, 2016 to “Neutral”, Firm has raised the Price Target to $ 33 from a previous price target of $30 .Avondale Initiated Diplomat Pharmacy Inc on Apr 19, 2016 to “Mkt Outperform”, Price Target of the shares are set at $38.Diplomat Pharmacy Inc was Initiated by Credit Suisse to “Neutral” on Mar 16, 2016.

Diplomat Pharmacy Inc. (Diplomat) is an independent specialty pharmacy in the United States. The Company provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups hospitals and health systems. The Company offers services in Specialty Drug Dispensing which includes its specialty infusion pharmacy services. The specialty drug dispensing services include Patient Care Coordination Clinical Services Compliance and Persistency Programs Patient Financial Assistance Specialty Pharmacy Training/Consulting (Diplomat University) Benefits Investigation Prior Authorization Risk Evaluation and Medication Strategy (REMS) Retail Specialty Services Hospital and Health System Services and Hub Services. The Company help patients adhere to complicated medication therapies process refills and manage any side effects and insurance concerns to ensure they get the standard of care.

Leave a Reply

Diplomat Pharmacy Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Diplomat Pharmacy Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.